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ABSTRACT: The worldwide prevalence of tobacco use is widespread, resulting in nearly 
4.5 million deaths every year. Nicotine is addictive and has psychopharmacological effects 
that maintain the use of tobacco products. Several studies have documented a strong heredi-
tary component to tobacco use. The present article reviews results from twin and adoption 
studies and proceeds to present association studies of specific genes that may be involved in 
tobacco use. Cholinergic receptor nicotinic beta polypeptide 2, serotonin receptor and trans-
porter genes, dopamine receptor and transporter genes, and the cytochrome P450A6 gene 
are reviewed. Linkage studies help to identify regions of the genome that may be worth fur-
ther investigation. The paper concludes with a discussion of the limitations of genetic re-
search and the future of genetic epidemiology in this domain. 
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EPIDEMIOLOGY OF TOBACCO USE 
AND DEPENDENCE 
Tobacco use and dependence are byproducts of 
a large, complex web of social, environmental and ge-
netic influences. Tobacco dependence essentially re-
sults from prolonged exposure to the pharmacologic 
effects of nicotine. Although smoking has been popular 
for more than a century, the addictive qualities of nico-
tine were not acknowledged in scientific literature until 
the 1980s. Consequently, despite the knowledge that 
tobacco use carries considerable health risks [1,2], more 
than 1.1 billion people (one-third of the global adult 
population) use tobacco regularly [3]. Current global 
estimates indicate that 48% of men and 12% of women 
smoke cigarettes [4]. Transnational consumption differ-
ences indicate that smoking is decreasing in most de-
veloped countries yet increasing in most developing 
nations. In the United States, 25% of the total popula-
tion aged 12 or older (56.3 million people) smoke ciga-
rettes, 5.4% (12.1 million people) smoke cigars, 3.2% 
(7.3 million people) use smokeless tobacco, and 1.0% 
(2.3 million people) smoke tobacco in pipes [5]. Among 
adult smokers, many wish to stop smoking, but the ad-
dictive qualities of nicotine create a complex barrier. In 
the United States, 70% of current smokers express a 
desire to quit, yet only 4.7% of those who attempted to 
quit in the past year were able to maintain abstinence 
from smoking for 3-12 months [2].  
Withdrawal difficulties are evident even in ado-
lescent smokers who try to quit [6]. Indeed, the age of 
smoking initiation is declining and tobacco use is rising 
among youth in many countries [7]. There are a number 
of complex and inter-relating factors that predispose 
young people to smoke, and these vary among indi-
viduals and among different populations. Low prices, 
easy access, parental smoking, family conflicts, peer 
pressure, and the positive image of smoking through 
advertisement are all contributing factors for tobacco 
use initiation in adolescence.  
 
CHARACTERISTICS OF TOBACCO USERS 
Although historically, adult tobacco use was 
linked to affluence [8], today, continuing tobacco con-
sumption is associated with societal disadvantage indi-
cators, such as low income and low education [9], and 
individual factors, such as race, use of alcohol or other 
illicit drugs, depression, and personality type [10]. 
There are differences in specific smoking behaviors 
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ics and Asians have lower smoking prevalences (19% 
and 14% respectively) than Caucasians or African-
Americans (about 25%) [2]. Reports indicate that Afri-
can-Americans start smoking regularly at a later age 
and smoke fewer cigarettes, but smoke those with 
higher nicotine content [11-13]. In terms of gender, 
differences may exist in nicotine sensitivity and nico-
tine requirements. For example, after smoking similar 
cigarettes, women have significantly lower nicotine 
levels than men [14]. Also, many studies show that al-
though men are more likely to be smokers, women tend 
to have greater difficulty quitting [10].  
Certain personality or behavioral traits, such as 
depression, neuroticism, attention deficit and hyperac-
tive disorder (ADHD), and novelty seeking are associ-
ated with tobacco use [10,15]. Novelty-seeking is char-
acterized by stimulation-seeking and sensitivity to 
reward or reinforcement, and is associated with nicotine 
dependence not only in adults [16], but also in adoles-
cents [17] and early age of smoking initiation [18]. 
Children and teenagers with a diagnosis of ADHD 
engage in more health-threatening behaviors such as 
smoking, and alcohol and substance abuse. Though the 
etiology of ADHD is not known, recent studies suggest 
that maternal smoking during pregnancy is a factor and 
that there is a strong genetic link to the disorder [19].  
In general, individuals who are tobacco-depend-
ent exhibit greater psychiatric comorbidities that may 
stem from a common etiologic basis involving neuro-
transmitter pathways and genetics. A prime example 
comes from the considerable and consistent evidence 
that smoking, alcohol, and depression are linked. Com-
pared to never smokers, smokers have more than twice 
the lifetime prevalence of major depressive disorder 
[20]. Prevalence of smoking increases with levels of 
current symptoms of depression [21] and smoking ces-
sation relapse is associated with increased symptoms of 
depression [20]. Furthermore, individuals with a com-
bined history of alcoholism and major depression are 
at a high risk to use smoking as a means of mood 
enhancement [22]. A common neurological thread to 
these disorders is the involvement of serotonin and 
dopaminergic depletion and their associated rewards of 
pleasurable feelings [10,23,24], which are discussed in 
the following section. Thus, genes involved in the dopa-
minergic system have been studied in relation to alco-
holism, depression and many other psychiatric disor-
ders, with positive results [25]. Considering that 
tobacco dependence is linked to such individual charac-
teristics that are shaped not only by environment, but 
also by genetics [10], it is not surprising that studies 
have found a strong hereditary component to tobacco 
use [26,27].  
 
PSYCHOACTIVE COMPONENTS OF TOBACCO 
Nicotine’s addictive characteristics are known to 
primarily result from its ability to bind to receptors in 
the brain, which then increase concentrations of neuro-
transmitters such as dopamine and serotonin in reward 
regions of the brain. Dopamine, affected by many stim-
ulants and addictive drugs, is involved in the mesolim-
bic reward pathway, which produces pleasurable feel-
ings. Recent human drug-reversal trials confirm that 
nicotine mediates reinforcement from smoking via do-
pamine, and that smoking behavior can be manipulated 
within the same subjects in opposite directions by alter-
nately stimulating and blocking dopamine [28].  
Dopamine is secreted partly by the release of se-
rotonin (5-HT), which is a key neurotransmitter in the 
reward pathway and a logical candidate to study in rela-
tion to smoking behavior. When nicotine binds to its 
receptors, serotonin secretion from the brain increases 
[29,30]. The reward pathway proceeds as serotonin 
stimulates enkephalin in the hypothalamus, which then 
inhibits GABA at the substania nigra, finally releasing a 
specified amount of dopamine at the nucleus accum-
bens, termed the “reward site” [31]. Another link be-
tween nicotine and serotonin has been seen in the rat 
hippocampus, where smoking clearly reduces serotonin 
binding to serotonin receptors 1 (5-HT1) and 5-HT1A 
[32]. Thus, nicotine not only increases serotonin release 
from the brain, but also decreases its reuptake in the 
hippocampus. Together, these effects make available a 
greater amount of serotonin, which ultimately stimu-
lates dopamine release. During withdrawal from nico-
tine, serotonin release is indeed reduced [30], and 
changes in mood seen in nicotine withdrawal may 
partly result from diminished serotonin transmission 
[33]. Accordingly, it has been hypothesized that people 
with a functional deficit in this dopamine pathway may 
be more prone to nicotine dependence [27]. 
To confirm the notion that smoking and nicotine 
affect the dopaminergic system in the human brain, 
neuroimaging techniques, such as positron emission 
tomography (PET), have been used to directly measure 
physiologic, pharmacokinetic and pharmacodymanic 
events in the same person following nicotine admini-
stration. These studies have shown that nicotine has 
rapid pharmacokinetics, changing cerebral blood flow 
and brain metabolism [34,35]. Compared to non-
smokers, smokers exhibit significantly increased pre-
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regions [36]. Furthermore, smoking may create a vi-
cious cycle of reward and deficiency; a recent study 
found that smoking seems to inhibit dopamine receptor 
D3 mRNA expression, thereby diminishing the reward-
ing effect of dopamine, leading to a reward deficiency 
state and creating motivation for continued smoking 
[37]. Indeed, phenotypes of interest have been deline-
ated with the help of PET studies. For example, in re-
sponse to monetary rewards, striatal and dopaminergic 
activity is different for smokers and non-smokers. A 
possible explanation is that a smoker’s brain interprets 
and reacts to rewards differently, and perhaps in a more 
impulsive and sensation-seeking manner, than a non-
smoker’s brain [38]. Another phenotypical finding is 
that changes in cerebral blood flow following nicotine 
administration are strongly correlated to self-reported 
craving for cigarettes and addiction as a motivation for 
smoking [34]. Thus, it seems apparent that nicotine’s 
effects are linked to neuroanatomical systems involved 
in the dopaminergic pathway, as well as arousal and 
reward. 
Complicating the epidemiology of tobacco de-
pendence is the notion that nicotine may not be the only 
psychoactive component found in tobacco. Primary 
evidence for this notion comes from the observation 
that nicotine can evoke a behavioral response that lasts 
much longer than the presence of nicotine in plasma 
[39]. Fowler and colleagues (1996) observed that smok-
ing, but not nicotine, decreases the brain levels of an 
important enzyme that breaks down dopamine, mono-
amine oxidase (MAO), by 30-40%, which may result in 
increases in dopamine levels [40]. Further PET studies 
indicate that the reduction in MAO B in smokers is 
most likely to occur gradually and require chronic to-
bacco smoke exposure [41]. 
Another reason to speculate that additional com-
ponents of tobacco use are involved is the recent obser-
vation that cotinine, the primary metabolite of nicotine, 
is bioactive as well [42]. Compared to nicotine, cotinine 
has a long pharmacological half-life (15-19 vs. 2-3 
hours) and may be 5-30 times less potent [39]. Recent 
studies observed that cotinine evokes nicotine-like 
pharmacological responses, such as antagonizing the 
effects of dopamine receptor agonists [39]. Considering 
that cotinine, like nicotine, can stimulate dopamine re-
lease, it is theoretically possible that cotinine could 
mediate the long-term behavioral actions of nicotine. 
However, many studies have ascribed no pharmacol-
ogical action to the compound; even in levels as high as 
ten times that attained from cigarette smoking, it has 
been found to have no observable acute or withdrawal 
effects in humans [43]. Other possible compounds of 
tobacco may reinforce dependence by irritating the 
mouth, throat or bronchial tree, and thereby enhancing 
the addictive potential of nicotine through altered sen-
sory cues [44]. Overall, while many components of 
tobacco continue to be investigated in their role in ad-
diction, it is clear that nicotine is at the core of neuro-
pharmacological actions for many users.  
Essentially, smokers alter their tobacco use to 
maintain enough levels of nicotine to act on neuro-
transmitters; therefore, genetic variation in the psycho-
logical need for nicotine, the ability to metabolize it, 
and the pathway to its pleasurable effects, ultimately 
influences if and how people use tobacco. Indeed, as 
smokers pass through stages from initiation to depend-
ence, there are many opportunities for genetic factors 
to influence behavior. Research suggests that certain 
genes may be unique to one stage of the smoking proc-
ess, while others influence several smoking characteris-
tics [45-47]. The following paragraphs present major 
positive findings in twin and adoption studies that pre-
dict the strong role of genetics. The review then pro-
ceeds to discuss the results of association studies for 
specific alleles involved in tobacco use, as well as ge-
nome-wide scans and linkage studies. 
 
TWIN AND ADOPTION STUDIES ON THE 
GENETICS OF SMOKING BEHAVIORS  
The twin pair study, which has long been a popu-
lar research design to investigate the role of genetics in 
disease causation [48], provided early evidence that 
there is a hereditary component to tobacco use. In 1958, 
there was a report of increased frequency of smoking 
among pairs of monozygotic male twins, as compared 
to dizygotic twins [49]; this observation implicated ge-
netics in the etiology of the habit. Since then, innova-
tive research designs in twins have attempted to quan-
tify the role of inheritance in various outcomes, in-
cluding initiation, intensity (current amount smoked), 
persistence (years of smoking), dependence and inabil-
ity to quit. Kendler and colleagues (1999) studied 1,898 
female twins in an effort to identify risk factors for ini-
tiation and dependence. They found that initiation was 
associated with low education, religiosity, increased 
neuroticism, extroversion and mental health comorbid-
ities. Nicotine dependence was associated with low 
education, extroversion, mastery, self-esteem, increased 
neuroticism, history of mood disorders and alcohol 
abuse [50]. A review of data from 14 different twin 
studies and more than 17,000 twins estimated that 
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smoking initiation and regular tobacco use, environ-
mental (shared, familial) risk factors account for 24% 
and individual risk factors account for the remaining 
20%. The authors note that genetic factors appear to be 
more prominent in the transition to nicotine depend-
ence, where they account for approximately 70% of the 
variance, and shared environmental influences seem 
negligible [47]. Elsewhere, smoking persistence (the 
number of years of regular smoking) has been found to 
be substantially due to genetic factors, with similar ef-
fects for women and men of all ages [46], although the 
role of environment, and especially low education, is 
significant. To estimate the heritability of failed smok-
ing cessation, Xian and colleagues (2003) studied 1,818 
twin pairs of smokers that had experienced at least one 
unsuccessful attempt to quit; they found that genetics 
accounted for 54% of the variance in risk of failed ces-
sation and 29.7% of the variance in the risk of nicotine 
withdrawal [51].  
In general, twin studies of both adolescents and 
adults indicate that the role of genetics is greater in de-
pendence and quantity smoked, than in initiation, where 
environmental influences prevail [45,52,53]. Initiation, 
like persistence, is largely influenced by important in-
teractions between environmental and genetic elements 
[54]. The notion that both environmental and inheri-
tance factors may co-exist, and the fact that this co-
existence is difficult to disentangle, create the potential 
for confounding or bias in twin studies. To avoid this 
problem, Osler and colleagues (2001) conducted an 
adoption study using 840 families [55]. Their finding 
that smoking status in adult adoptees was significantly 
associated with the smoking status of the biological full 
siblings, who were reared separately, supports the re-
sults of twin studies and strengthens the notion that 
there is a genetic influence on smoking [56].  
 
GENETIC ASSOCIATION STUDIES 
The fact that smoking is a complex process in-
volving many different molecular targets has led to 
proposals to study a variety of genes as modulators of 
smoking behavior. To identify exactly which gene vari-
ants are associated with smoking phenotypes, molecular 
epidemiology has primarily used the candidate gene 
approach. For complex psychiatric disorders such as 
substance abuse, no single genetic locus is itself the 
causal factor; rather, multiple alleles found at various 
loci interact to produce vulnerability to an outcome. 
Unfortunately, the ability to identify numerous alleles 
that each contribute small effects, or that have an effect 
only when other critical alleles are also present, is poor, 
and studies are often under-powered [57]. Still, varia-
tions in the genome that have functional consequences 
(e.g., an important protein changes in the amount, loca-
tion, or structure of expression in carriers of that allele) 
can be studied with success given adequate sample 
sizes and plausible mechanisms of action [58].  
Advances in technology, together with the unique 
ability of these genetic variations to facilitate gene iden-
tification, have resulted in a recent flood of detection of 
single nucleotide polymorphisms (SNPs), which are 
often implicated in genetic association studies. Another 
recent focus of genetic research is the study of haplo-
types, which are specified variants in an entire region of 
a chromosome, rather than just at one locus or gene. A 
‘haplotype map’ is currently being constructed, to better 
pinpoint areas of chromosomes that are of interest dur-
ing future research. Further information and updates on 
genetic research can be found at the National Center for 
Biotechnology Information web site: http://www.ncbi. 
nlm.nih.gov. 
To investigate variant alleles and their role in 
smoking behavior, studies have focused on polymor-
phisms involved with the pathway of pleasurable sensa-
tions conferred by tobacco use, such as the dopamine 
system, as well as those involved in the metabolization 
of nicotine, such as genes that code for proteins in the 
cytochrome P450 family. The prominent outcomes that 
have been studied are smoking initiation, progression to 
nicotine dependence, quantity smoked, and persistence 
of smoking. Increasingly, endophenotypes, such as ini-
tial sensitivity to nicotine, are also being considered to 
further the power and interpretation of studies.  
 
NEUROTRANSMITTER PATHWAYS 
Since the effects of nicotine on the dopamine 
pathway are relatively well understood, many studies 
have investigated genetic variations in the dopaminer-
gic system. Genes for this neurotransmitter’s synthesis, 
degradation, receptors, and transporters are logical can-
didates. At the same time, serotonin, norepinephrine, 
GABA (gamma amino butyric acid), opioid, and can-
nabinoid neurons all modify dopamine metabolism and 
dopamine neurons. For example, mu-opioid receptors 
are known to play an important role in mediating the 
effects of various substances, such as opioids [59,60], 
cannabinoids [61] and alcohol [62]. 
Recently, it was shown that mice lacking mu-
opioid receptors do not obtain rewarding effects of 
nicotine and have reduced withdrawal symptoms, sug-
gesting a functional interaction between nicotine, the 
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opioid system, and dopaminergic mesolimbic activity 
[63]. It has been proposed that defects in various com-
binations of the genes for these neurotransmitters result 
in a Reward Deficiency Syndrome (RDS) and that such 
individuals are at risk for abuse of substances that pro-
vide unnatural rewards [64].  
In addition to this dopamine pathway, other 
neuronal systems, including brainstem cholinergic, 
GABAergic, noradrenergic and serotonergic nuclei, are 
also affected by nicotine and may be involved in nico-
tine dependence [65]. Much of the current knowledge 
of these systems comes from observations of the behav-
ior of mice with mutations. Thus, the mechanisms of 
neurotransmitters, such as norephinephrine, or other 
pathways that are independent of the dopamine path-
way, such as those following nicotinic reception in the 
brainstem, are yet to be determined [65]. While animal 
models are critical to the understanding of genetic fac-
tors in complex behavior, the following discussion con-
centrates on studies of smoking behavior in human 
populations and their associations with neurotransmit-
ters with known polymorphisms.  
 
NICOTINIC RECEPTORS 
Reward pathways are initiated when nicotine 
binds to nicotinic acetylcholine receptors (nAchRs), 
which then mediate the positive and negative effects 
that follow. Two classes of these receptors have been 
identified and many subunits are expressed in key re-
gions of the brain and the mesolimbic dopamine sys-
tem. One receptor gene, CHRNB2 (cholinergic recep-
tor, nicotinic, beta polypeptide 2, located on chromo-
some 1q21) is a functional candidate gene for nicotine 
dependence, since it seems to be essential for a number 
Table 1.  Epidemiologic studies of tryptophan hydroxylase (TPH) gene, serotonin transporter gene and 
tobacco use in human populations. 
First Author, 
Year 
Population, 
Sample size 
Gene  Statistically Significant (p<0.05) Results  
Lerman 
2001 
USA 
N=451 
TPH A/A, 
A/C, C/C 
A/A genotype is associated with younger age at smoking ini-
tiation 
Sullivan 2001  USA 
N=780 
TPH C218A 
and C779A 
Allele frequency, genotype, and haplotype are associated with 
smoking initiation 
Lerman 
2000 
USA 
N=185 smok-
ers  
Serotonin 
Transporter  
5-HTTLPR 
S/*
a vs. L/L 
Interaction between genotype and neuroticism in nicotine in-
take, dependence and smoking motivations; neuroticism pre-
dicted these behaviors among smokers with the S allele, but 
not among those with the L allele (no significant main effects 
of genotype) 
Hu  
2000 
USA 
N=759  
Serotonin 
Transporter  
5-HTTLPR 
S/* vs. L/L 
Interaction between genotype and neuroticism in smoking 
status, initiation and cessation; neuroticism predicted these 
behaviors among smokers with the S allele, but not among 
those with the L allele (no significant main effects of geno-
type) 
Ishikawa 1999  Japan 
N=496 men  
Serotonin 
Transporter  
5-HTTLPR 
L/* vs. S/S 
L allele predicts increased smoking
b and greater number of 
cigarettes/day 
Lerman  
1998 
USA 
N=498  
Serotonin 
Transporter  
5-HTTLPR 
S/S, S/L, 
L/L 
No significant differences by genotype 
a.  A * denotes an allele other than the one noted  
b.  Increased smoking refers to comparisons between current, former and never or non-smokers (reference group) 
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ever, a study of four SNPs in CHRNB2 found no asso-
ciation with the polymorphisms or their estimated hap-
lotypes with smoking initiation or nicotine dependence, 
using carefully selected samples of non-smokers and 
regular smokers [66]. Polymorphisms in several other 
receptor subunits have since then been identified [67, 
68]. If new polymorphisms prove to have functional 
significance, then these genes may be candidates to 
explore in future research in smoking behavior [56]. 
 
SEROTONIN  
 
Serotonin Synthesis Neurotransmitter, 
Tryptophan Hydroxylase Gene (TPH) 
Tryptophan hydroxylase (TPH) catalyzes the rate-
limiting step in serotonin biosynthesis. Although the 
known polymorphisms in the TPH gene are in non-
coding regions and are not thought to have functional 
consequence [69], two polymorphisms, C218A and 
C779A, have been linked to personality traits [70] and 
have been studied in association with smoking (Table1) 
[71,72]. These polymorphisms were not found to be 
associated with smoking status or progression to nico-
tine dependence. Significant associations, however, 
were seen in smoking initiation variables, such as age at 
onset of smoking [72] and ever having smoked more 
than an entire cigarette [71]. Considering the lack of 
functional significance of the polymorphisms and the 
possibility of false positive results, it is likely that either 
the TPH markers are in linkage disequilibrium for an 
unknown functional polymorphism, that the action of 
TPH on smoking is indirect (i.e., through a personality 
trait), or that TPH plays a minor role in the large web of 
causal factors for smoking initiation [71].  
 
Serotonin Receptor Gene 
Although there have been no reports of associa-
tion studies between serotonin receptor gene polymor-
phisms and smoking, studies have provided grounds to 
explore the relationship [33]. For example, the effect 
of a polymorphism in the 5-HT2C receptor gene 
(Cys23Ser) on the reward dependence trait was signifi-
cantly modified by the presence of a dopamine poly-
morphism (DRD4 VNTR) in individuals [73].  
 
Serotonin Transporter Gene 
Unlike the receptor gene, serotonin transporter 
gene (SLC6A4) polymorphisms have been studied in 
association with smoking behavior (Table 1). The sero-
tonin transporter gene, on chromosome 17q12, regu-
lates the reuptake of serotonin from the synaptic junc-
tion. Gene transcription is modulated by a polymorph-
ism (5-HTTLPR) that results in a long allele (l) or a 
short allele (s), which occur in 57% and 43% of Cauca-
sians, respectively [74]. The s allele is associated with 
reduced transcription, resulting in a lower 5-HTT up-
take and more available serotonin [75]. In addition, 
the s allele is associated with neuroticism, an anxiety-
related personality trait [74], in samples from the 
United States, Japan and Israel [15].  
The hypothesis that the increased available sero-
tonin in individuals with the s allele would protect 
against habitual smoking or help in the smoking cessa-
tion process has been tested. No association between 
the 5-HTT polymorphism and smoking was seen in a 
study of Caucasians and African-Americans [76]. In 
contrast, a study of Japanese men found that the l allele 
was observed significantly more often in smokers than 
in nonsmokers or ex-smokers [77]. Although the sub-
jects in the U.S. study were recruited through ads and 
may not have been representative of all smokers, the 
Japanese study differs from other studies by combining 
the l/l and l/s genotypes (since the l allele frequency 
tends to be lower in Japanese, at roughly 19%). There-
fore, more studies are needed to confirm that there is a 
main effect of the serotonin transporter gene polymor-
phism on smoking behavior. 
Meanwhile, an interaction between the trans-
porter’s 5-HTT polymorphism and neurotic personality 
has been found in two studies of smoking behavior [15, 
78]. For individuals with the s allele, neuroticism is 
linked to increased nicotine intake, dependence, smok-
ing for stimulation, and smoking to reduce negative 
affect. In contrast, neuroticism is not an important im-
pediment to smoking cessation for individuals with the 
l/l genotype, although they may exhibit the personality 
as well. Thus, rather than influence smoking initiation, 
these genotypes affect dependence, ability to quit, and 
motivations for smoking, such as smoking to self-
medicate mood disturbances [15]. More work is needed 
to clarify the role of polymorphisms in serotonin genes, 
so that drugs used in tobacco cessation, such as the se-
rotonin uptake inhibitor fluoxetine, can be administered 
to those people who would be most likely to benefit.  
 
Dopamine Transporter Gene (SLC6A3) 
Released dopamine is taken up by the presynaptic 
neuron via the dopamine transporter (DAT), which is 
the primary mechanism for dopamine clearance from 
the synapse in the midbrain. The DAT protein is en-
coded by the locus SLC6A3 on chromosome 5p15.3. At
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and tobacco use in human populations. 
First Author, 
Year 
Population, 
Sample size 
Gene  Statistically Significant (p<0.05) Results  
Erblich 
2004  
 
 
USA  
N=108 smokers 
 
SLC6A3-9/*
 a vs. 
10/10 
 
DRD2 A1/*
 a vs. 
A2/A2 
SLC6A3-9/* increases number of cigarettes/day 
  
SLC6A3-9/* & DRD2  A1/* exhibit greater ciga-
rette craving reactions 
 
Additive interaction of both gene variants 
Vandenbergh 
2002  
USA  
N=595 
SLC6A3-10/10, 
 9/10, 9/9 
SLC6A3-9/* predicts increased smoking
b 
Yoshida 2001   Japan 
N=332 
DRD2 A1/A1, 
A1/A2, A2/A2  
A2 predicts increased smoking 
Wu 
2000  
USA 
N=140 lung cancer 
cases and 222 controls 
DRD2 A1/A1, 
A1/A2, A2/A2 
 
DRD2 B1/B1, 
B1/B2, B2/B2 
DRD2 predicts increased smoking, pack-years 
and number of cigarettes/day  
 
A1 & case status interact to increase risk of fam-
ily history of smoking-related cancer 
Beirut 
2000  
 
 
USA  
N=970 Alcoholism 
study subjects and their 
first-degree relatives 
DRD2 A1/* vs. 
A2/A2 
 
No significant differences by genotype 
Lerman 
1999 
 
 
USA 
N=522  
DRD2 A1/* vs. 
A2/A2 
 
SLC6A3-9/* vs. 
*/* 
SLC6A3-9/* predicts non-smoking, older age at 
initiation of smoking, and longer previous quit 
attempts  
  
DRD2-A1/* predicts smoking only through inter-
action with SLC6A3 
Sabol 
1999 
 
 
USA 
N=1,107 
SLC6A3-9/* vs. 
*/* 
 
DRD2 A1/* vs. 
A2/A2 
SLC6A3-9/* predicts smoking cessation & low 
novelty-seeking  
Spitz 
1998 
USA 
N=283 
DRD2 A1/* vs. 
A2/A2 
 
DRD2 B1/* vs. 
B2/B2 
DRD2 A1/* or B1/* predict increased smoking, 
younger age at initiation & fewer attempts to quit 
Comings 
1996 
USA 
N=1026 (479 of which 
are from literature) 
DRD2 A1/* vs. 
*/* 
DRD2 A1/* predicts smoking 
Noble 
1994 
USA 
N=354  
DRD2 A1/* vs. 
A2/A2 
DRD2 A1/* predicts increased smoking 
Smith 
1992 
 
 
USA 
N=232  
DRD2 A1/* vs. 
A2/A2 
 
DRD2 B1/* vs. 
B2/B2 
DRD2 A1/* or B1/* predict increased substance 
use 
a.  A * denotes an allele other than the one noted  
b.  Increased smoking refers to comparisons between current, former and never or non-smokers (reference group) 
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number of tandem repeats (VNTR) in the 3’-
untranslated region, with repeat numbers ranging from 
3 to 11. The most common allele in population studies 
is the ten-repeat allele (A10, about 70% in European, 
Caucasian or African-Americans), followed by the 
nine-repeat allele (A9, about 25% in European, Cauca-
sian or African-Americans). However, there is some 
regional variation; A10 is seen in more than 90% of 
Asian or South American populations, and certain Afri-
can populations have high frequencies of the A7 allele. 
Although the VNTR polymorphism does not affect the 
actual protein product, it may affect mRNA localiza-
tion, transcript stability, regulation of protein synthesis, 
and expression [79]. Indeed, the polymorphism seems 
to alter translation of the DAT protein and decrease its 
availability [80-82]. Under certain conditions, a de-
crease in transporter proteins decreases the clearance of 
synaptic dopamine. As a result, the baseline “set point” 
of synaptic dopamine is higher, thereby increasing sen-
sitivity to drug-induced dopamine surges, or decreasing 
desire for substances, such as nicotine, that would in-
crease synaptic dopamine [82].  
 
Dopamine Receptor Gene (DRD) 
The synaptic levels of dopamine may also be de-
termined by the density of dopamine receptors, which 
involves the dopamine receptor gene (DRD). Although 
there are many dopamine receptors (D1-D5), each ex-
hibiting polymorphisms, the D2 dopamine receptor 
gene has been the focus of research regarding substance 
abuse. This is primarily due to the lack of evidence that 
the other polymorphisms have functional significance 
or are related to other complex psychiatric disorders 
[83]. The D2 receptor gene is located on chromosome 
11q.23, and several polymorphisms have been identi-
fied, most notably in the TaqI A allele (A1 and A2) and 
the TaqI B allele (B1 and B2). Studies suggest that 
there is linkage disequilibrium between the less com-
mon A1 and B1 allele variants [84-86]. There is consid-
erable variation in the frequency of these alleles in 
different racial and ethnic populations, even within 
European-American samples [87]. The A1 allele has 
been correlated with a reduced number of dopamine 
binding sites in the brain [84,88-90], and with increased 
dopamine transporter levels [91]. Heterosis, which re-
fers to the situation where heterozygotes for an allele 
(e.g., A1/A2) are more likely to exhibit a phenotype 
than either homozygote (e.g. A1/A1 or A2/A2), was 
reported in the effect of the DRD2 gene on D2 receptor 
density [92].  
Another DRD polymorphism that seems to have 
functional significance and has been studied in relation 
to smoking is the DRD4 VNTR polymorphism, on 
chromosome 11p15.5. There are three common variants 
of two (D4.2), four (D4.4), and seven repeats (D4.7) 
[93], which occur within coding regions. The longer, 
seven-repeat variant appears to blunt the intracellular 
response to dopamine in vitro, as compared with the 2 
and 4 repeat variants [94]. D4 receptors are structurally 
and pharmacologically very similar to D2 receptors and 
are localized to the same limbic brain structures that 
underlie reward feelings [95]. It has been found that D4 
receptors in the nucleus accumbens (the reward site) 
may modulate excitatory transmission [96] and the sen-
sitization of these pathways [97].  
 
The Role of the SLC6A3 and DRD in Tobacco Use 
The hypothesis that people with altered transport 
or a reduced D2 receptor density have a deficit in their 
reward system and feel an enhanced reward when ex-
posed to dopaminergic agents, thereby making them 
more prone to nicotine addiction, has been supported 
by epidemiologic studies (Table 2) [27,85,86,98-105]. 
However, the findings regarding behavioral phenotypes 
associated with certain alleles are contradictory and 
indicate that the exact role of dopamine genes is com-
plex. Although explanations for inconsistent findings 
are discussed in a subsequent section, it is worth noting 
here that heterosis in the effects of dopamine genes may 
play a role [89,106,107].  
With this in mind, the SLC6A3-9 allele has been 
found to be associated with an increased susceptibility 
to tobacco use in some studies [103,104], but a de-
creased susceptibility in others [100,108]. Earlier stud-
ies comparing those who have smoked <100 cigarettes 
in their lifetime (designated as non-smokers) to either 
former or current smokers found that carrying at least 
one copy of the 9 allele decreases risk of smoking by 
almost 50% and is associated with a four-fold higher 
likelihood of successful smoking cessation [103,104]. 
The notion that SLC6A3 is associated with smoking 
cessation was also supported by a recent case-control 
analysis using 250 current smokers [109].  
Opposing findings, in which the 9 allele signifi-
cantly increases the likelihood of smoking, may be 
partly due to the distinction made between never-
smokers (never inhaled the smoke from even one ciga-
rette) and non-smokers (smoked 1-100 cigarettes in 
lifetime) [100]. This distinction is likely to be impor-
tant, particularly if risk-taking personality is a factor. 
The notion that the SLC6A3-9 allele may increase risk 
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notype of self-reported craving; smokers with at least 
one copy of the 9 allele had significantly greater crav-
ing reactions following a laboratory-induced stress 
[108]. Interestingly, despite disagreement regarding the 
direction of the association of the SLC6A3-9 allele, 
studies agree that there seems to be a significant inter-
action between this gene and DRD2-A1 in increasing 
susceptibility to tobacco use [103,108]. An acceptable 
postulated mechanism is that individuals with certain 
SLC6A3 genotypes have lower endogenous synaptic 
dopamine, and therefore a greater need to use sub-
stances such as nicotine to stimulate dopamine trans-
mission. This unfavorable effect of decreased dopamine 
may be especially pronounced in people with DRD2-
A1 genotypes, i.e., those with deficient receptor den-
sity.   
In general, the evidence for the DRD2 TaqI A1 
allele is more consistent and points to an increased risk 
of tobacco use. Studies have found significant main 
effects with younger age at smoking initiation [86, 
105], fewer attempts to quit [86,104], shorter duration 
of quit attempts, current or past smoking [27,85,105] 
and craving reactions [108], but not nicotine addiction 
scales [86]. Recent investigations have found that 
DRD2 is associated with withdrawal symptoms, such as 
difficulty in concentrating and sleeping, and that DRD3 
is associated with age of initiation, heaviness of smok-
ing, and depression during withdrawal [99]. Meta-
analyses based on three studies suggest that the odds 
ratio for likelihood of drug abuse is 2.4 for individuals 
possessing an DRD2-A1 allele and 3.3 for those having 
a DRD2-B1 allele (p<0.001 in both cases) [110]. The 
notion that the A1 allele increases susceptibility to to-
bacco use is supported pharmacologically by random-
ized trials of bupropion hydrochloride, a weak dopa-
mine reuptake inhibitor effective in decreasing with-
drawal symptoms and craving. Studies have found that 
bupropion attenuates withdrawal-related craving, irrita-
bility and anxiety only among subjects with the DRD2-
A2/A2 genotype [111,112]. A plausible biological hy-
pothesis is that dopamine reuptake inhibition during 
nicotine withdrawal is less pronounced in DRD2-A1 
carriers, since they have a limited ability to stimulate 
postsynaptic dopamine receptors in the brain’s reward 
regions [90].  
The association between DRD4 variants and 
smoking has been studied independently of the DRD2 
and SLC6A3 polymorphisms, but results are similarly 
complicated (Table 3). Regarding the main effects of 
DRD4 in smoking initiation, dependence and persis-
tence, analyses of Caucasians have found no association 
[23,113,114], but an African-American sample showed 
that presence of at least one long (L, 6-8 repeats) allele 
conferred an OR of 7.7 (95% CI 1.5, 39.9) for risk of 
smoking and a significantly shorter time to first ciga-
rette in the morning [113]. In a combined sample, a 
significant interaction was seen between depression and 
DRD4, in which depressed smokers homozygous for 
the short alleles of DRD4 were more likely to smoke to 
reduce negative feelings and to smoke in response to 
stimulation [23]. The notion that smoking cues (e.g., 
seeing a lit cigarette) are important in the mechanism of 
D4 variants was further supported by a recent study, in 
which only individuals with long-repeats alleles showed 
significant reactions to smoking cues, in particular in-
creased craving and arousal, with decreased positive 
affect [114]. The exact mechanism of affecting the re-
action to smoking cues has been speculated, but re-
quires verification by molecular studies [114].  
Of note, a recent study simultaneously analyzed 
linkage and association of the DRD4 genotype to smok-
ing, alcohol and novelty-seeking behaviors in a sibling-
pair design [115]. In the second wave of the study, 
DRD4 had a significant effect on smoking status, but 
the authors admit that the number of statistical tests 
performed and the inconsistency of the gene effect over 
time invalidate this finding. Thus, with improved meth-
ods, considerable power, repeated measures for some 
phenotypes, and strengths of having gender-, age-, and 
ethnicity-specific analyses, results showed no evidence 
that DRD4 variation has any affects on the outcomes. 
Although family studies and linkage analysis are dis-
cussed in other sections of this review, it can be noted 
here that a combination of linkage and association 
analysis, as was done by Luciano and colleagues, is 
likely to offer greater power and validity [115]. Conse-
quently, the argument for a role for DRD4 in tobacco 
use is considerably weakened.  
 
Dopamine Metabolizers 
Polymorphisms in genes that code for dopamine-
metabolizing enzymes have also been linked to smok-
ing behavior [116]. For example, the gene for monoam-
ine oxidase A (MAO-A) has a point mutation (GÆC) 
polymorphism causing an MAO-A deficiency. This 
polymorphism has been linked both to abnormal 
aggressiveness [117] and elevated brain levels of 
serotonin and dopamine [118]. A study in smokers 
found that individuals with the MAO-A 1460 TT/TO
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compared to those with CC/CT/CO (RR: 2.9, 95% CI: 
0.6- 5.1, p = 0.013) [116]. The C allele was less fre-
quent in heavy smokers (>20 cig/day) compared to light 
smokers (<10 cig/day) (RR: 0.3, 95% CI: 0.1-0.7, p = 
0.012). Another enzyme, dopamine B-hydroxylase 
(DBH), was also found to be associated with amount 
smoked per day. However, this finding reached statisti-
cal significance only in women, and the effect was 
small (those with the DBH 1368 GG genotype smoked 
3.8 fewer cig/day). Heavy smokers were more likely to 
have the DBH 1368A allele, compared to light smokers 
(RR 2.3, 95% CI 1.1-5.0, P = 0.024). 
Since cigarette smoking reduces the activity of 
MAO-A [40,119] and other enzymes, the relationship 
between these factors is complex and needs clarifi-
cation. Future studies may also like to consider func-
tional polymorphisms in MAO-B and catechol-O-
methyltransferase (COMT), which also metabolize 
dopamine [33]. 
 
Nicotine Metabolization Pathways: CYP2A6 
Genetically-based individual variation in the me-
tabolization of nicotine presents an additional pathway 
by which polymorphisms may influence smoking be-
havior. In humans, approximately 70-80% of nicotine is 
metabolized into cotinine [42], primarily by the enzyme 
cytochrome P450 2A6 (CYP2A6) [120,121]. This 
enzyme, responsible for the clearance of numerous 
chemicals, is predominantly expressed in the liver but 
also in respiratory organs [121]. Considerable interindi-
vidual variability in the activity of CYP2A6 has been 
seen in studies of human liver microsomes [122-125], 
as well as phenotyping studies using various ethnic 
populations [126-129]. Specifically, greater than 30-
fold variation in nicotine-to-cotinine Vmax values [120]
Table 3.  Epidemiologic studies of dopamine receptor gene (DRD4) and tobacco use in human populations. 
First Author, 
Year 
Population, 
Sample size 
Gene  Statistically Significant (p<0.05) Results  
Luciano 2004  Australia 
N=769 single 
twins  
DRD4  
48-base pair 
repeat poly-
morphism 
No significant association or linkage tests  
 
 
Hutchinson 
2002 
USA 
N=68 
 
DRD4  
L/*
 a vs. S/S 
Interaction between genotype and response to smoking cues: 
DRD4 L/*, but not S/S, have increased craving, attention, 
arousal, and decreased positive affect during exposure to 
smoking cues 
 
No main effect of DRD4 on novelty seeking, nicotine depend-
ence, smoking history or response to smoking cues.   
 
Lerman 1998  USA 
N=231 
smokers  
DRD4  
L/* vs. S/S 
Interaction between depression and genotype:  depressed 
smokers with S/S are more likely to practice stimulation smok-
ing and negative-affect reduction smoking; effect not seen in 
L/* genotypes  
 
No main effect of DRD4 on depression, stimulation smoking, 
negative-affect reduction smoking or nicotine dependence. 
Shields 1998  USA 
N=430 
DRD4  
L/* vs. S/S 
In African-Americans: L/* predicts increased smoking, shorter 
time to first cigarette in the morning and earlier age at smoking 
initiation.  No L/* genotype smokers were abstinent 2 months 
after smoking cessation counseling, vs. 35% of S/S genotype 
smokers  
 
No significant association with genotype and smoking in Cau-
casians. 
a.  A * denotes an allele other than the one noted  
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Table 4.  Epidemiologic studies of cytochrome P450 2A6 (CYP2A6), nicotine metabolization and tobacco use 
in human populations. 
First Author, 
Year 
Population, 
Sample size 
Gene
a  Statistically Significant (p<0.05) Results  
Xu 
2002 
Canada  
N=14 in ki-
netic sub-
study  
N=478 in 
allele fre-
quency study 
Wild-type 
CYP2A6*1
/*1 vs.  
*4/*4, 
*4/*10, 
*4/*7, 
*7/*7, 
*1/*8  
 
 
Homozygous wild-type genotypes CYP2A6*1/1 have lower 
plasma levels of nicotine and higher levels of the CYP2A6-
mediated nicotine metabolite cotinine, compared to those with 
the null *4/4 genotype (6 hours after oral administration of nico-
tine) 
 
*7/*7 genotypes or *7 in combination with gene deletion have 
intermediate levels of nicotine   
 
One individual containing both *7 and *8 (CYP2A6*4/*10) has 
sharply reduced metabolism of both nicotine and cotinine  
Rao  
2000 
Canada 
N=296 
smokers 
CYP2A6*1
/*1 vs. 
*1/*4, *1/2, 
*2/2, or 
*1/*1 plus 
duplication  
Smokers with reduced activity or null alleles (*2/2, *1/2 or *1/4) 
use fewer cigarettes/day compared to those with wild-type 
(*1/*1) genotype both currently (13.5 + 2.3 vs. 19.5 + 0.7) and 
at time of heaviest smoking (19 vs. 29), and have lower cotinine 
levels  
Kitagawa 1999  Japan 
N=11 smok-
ers in smok-
ing challenge 
sub-study 
N=252 in 
genotype 
study  
CYP2A6*1
/1 vs. ho-
mozygous 
deletion 
Homozygous wild-type genotypes CYP2A6*1/1 have higher 
cotinine concentrations in urine than homozygously deleted 
genotypes (average concentration 3.87 + 1.64 vs. 0.40 + 0.15 
3g/ml at 1.5 hours after smoking for 1 hr.) 
 
On average over the 24-hr period following smoking challenge, 
cotinine excretion in homozygously deleted genotypes was one-
seventh compared to control group (p<0.001) 
Pianezza 1998  Canada 
N=428  
CYP2A6*1
/1 vs. null 
alleles *2 
or *3 
Dependent smokers have lower frequency of null alleles, com-
pared to the never-dependent control group (12.3% vs. 19.6%, 
p<0.04, OR=1.74, 95% CI 1.02-2.94) 
 
Smokers heterozygous for null alleles have fewer number of 
cigarettes/week (129 vs. 159, t-test p<0.02), compared to smok-
ers with two active alleles  
a.  We have used the nomenclature system for CYP2A6 alleles recommended by the Human Cytochrome P450  
Allele Nomenclature Committee (available at http://www.imm.ki.se/CYPalleles/) 
was revealed in a study of human liver microsomes. 
Although environmental compounds can affect its ac-
tivity, either inducing the enzyme (e.g., phenobarbital) 
or decreasing its expression (e.g., nicotine) [130,131], 
the CYP2A6 gene also expresses genetic polymor-
phisms that may contribute to the variation in nicotine 
metabolism and therefore smoking behavior. 
Numerous alleles have been found for the 
CYP2A6 gene locus on chromosome 19 (19q12 – 
19q13.2). The wild-type, which is fully functional to 
metabolize nicotine, is the CYP2A6*1 allele. The pri-
mary null alleles are the *2, *4, *5 alleles. Since these 
null alleles code for inactivity, individuals homozygous 
for these alleles cannot metabolize nicotine through the 
CYP2A6 pathway. Other defective alleles (*6, *7, *9, 
*10, *11, *12) have reduced activity. Furthermore, a 
duplicate wild-type allele has been found, which con-
fers increased activity. The frequencies of the defective 
alleles are low (1-3%) in Caucasian and European 
populations, but more common in Asian populations, 
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Although allele frequencies in African-Americans have 
not been reported, this group tends to have a generally 
decreased nicotine clearance, which may be due to de-
creased CYP2A6 activity [134]. Also, males tend to 
have faster rates of nicotine metabolism than do women 
[120,135,136]. 
The finding that smokers adjust the amount and 
intensity of their smoking to maintain peripheral and 
central nicotine levels [137,138] provides the basis for 
the proposed mechanism by which the defective alleles 
influence smoking behavior. The hypothesis is that 
those who carry a variant allele maintain greater levels 
of nicotine in their system for longer time periods after 
a given dose of tobacco; therefore, they need less exter-
nal sources of nicotine. An additional consequence of 
a slower metabolism of nicotine is that bothersome 
effects of nicotine may be more pronounced. Thus, peo-
ple with defective alleles may be more sensitive to 
tobacco products and less likely to become regular or 
dependent users [120].  
Studies testing this hypothesis confirm that after 
oral administration of nicotine [139] or cigarette smok-
ing [140], those with the defective alleles, compared to 
homozygotes for the functional allele, have signifi-
cantly higher plasma levels of nicotine and lower levels 
of cotinine (Table 4). Furthermore, studies have found 
that individuals with defective alleles smoke fewer 
cigarettes per day and are less likely to become nicotine 
dependent [141,142]. Specifically, one study of 296 
Caucasian men and women found that smokers who 
carry the null *2 or *4 alleles smoked fewer cigarettes 
per day both currently (13.5 + 2.3 vs. 19.5 + 0.7, 
p<0.03) and at the time of heaviest smoking (19 vs. 29, 
p<0.001), had lower breath carbon monoxide levels, 
and had lower cotinine levels than did individuals ho-
mozygous with the wild-type *1 fully functional allele. 
Interestingly, people carrying CYP2A61/1 plus duplica-
tion had higher carbon monoxide and cotinine levels, 
but reported smoking fewer cigarettes per day, than did 
people with either a single copy of the active or defec-
tive alleles. The authors hypothesize that those with the 
duplicate gene smoke more intensely, rather than more 
frequently, in order to maintain their nicotine levels 
[141]. A separate study confirmed findings that nicotine 
and cotinine levels significantly vary by genotype ac-
cording to level of enzyme activity associated with the 
allele. For example, people with the 1/1 genotype had 
the lowest plasma levels of nicotine and highest levels 
of cotinine, while people carrying the defective *7 al-
lele had intermediate levels, and those carrying the null 
*4 allele had the highest levels of nicotine and lowest 
levels of cotinine [139].  
Other cytochrome P450 enzymes that have been 
found to be involved in the metabolism of nicotine in-
clude CYP2B6 and CYP2D6; however, their contribu-
tions are minor [120,121]. In human liver microsomes, 
CYP2B6 was found to be involved in nicotine C-
oxidation at high, but not low, substrate concentrations. 
CYP2D6, on the other hand, is unlikely to have a role 
in nicotine metabolism, according to recent findings 
[121,143].  
In summary, studies have found polymorphisms 
in CYP2A6 to be associated with risk of tobacco-
dependence, amount smoked, various smoking indices, 
and tobacco-related cancer [133,144]. The complexity 
of the role of cytochrome P450 is increased by the fact 
that environmental chemicals and drugs may induce its 
activity, therefore affecting the overall clearance of 
nicotine from the body [120,131]. Another concern is 
that these polymorphisms are quite rare in Caucasian 
populations, thereby limiting the ability to study the 
role of CYP2A6 in nicotine metabolism and smoking 
behavior. However, if variant alleles do indeed affect 
metabolism and smoking behavior, then the efficacy of 
nicotine-replacement therapy can be greatly increased 
by identifying and using inhibitors of CYP2A6 [145-
147]. Therapeutic use of CYP2A6 inhibitors to mimic 
the decreased activity of variants may produce the same 
benefits of the null alleles and provide new approaches 
to prevention and treatment of tobacco use. 
 
LINKAGE STUDIES 
While the goal of association studies is to identify 
specific alleles, linkage analysis aims to identify re-
gions of the genome likely to be involved in suscepti-
bility to tobacco use. In 1999, a complete genome scan 
revealed that there are many regions with numerous 
consecutive markers that yield small but positive results 
of linkage to a dichotomous outcome of nicotine de-
pendence [148]. However, further investigation into 
regions of chromosomes 2, 4, 10, 16, 17 and 18 failed 
to find any significant linkage. Despite inconclusive 
findings, the authors of this study re-analyzed this 
affected sibling pair data in 2004 for a hypothesis-
generating study of nicotine dependence candidate 
genes, via linkage, epistasis and bioinformatics. The 
recent analysis suggests that the results of the genome 
scan were more informative than initially perceived, 
and indicates a possible etiological relevance for 10 
genomic regions. In particular, a broad region on chro-
mosome 2 (2q22.1-2q24.1) and a narrower region on 
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rigorous Lander and Krugylak [149] criteria for “sig-
nificant” linkage. The analysis also searched for 
genome-wide epistatic interactions and found four cor-
relations of interest, one of which (correlation of 
D8S1145 with D22S444) was particularly large and 
unlikely to be due to chance. Interpretation of the 
epistatic correlations is hampered, however, by the fact 
that markers in each correlated pair did not have size-
able positive NPL Z scores [150].  
To clarify the significance of these results and to 
form hypotheses on candidate genes in nicotine de-
pendence, the authors looked for agreement between 
genes located in the 10 regions statistically implicated 
in their analyses with a list of genes suggested by mi-
croarray studies and human association studies. Corre-
spondence was found for genes involved with the mito-
gen-activated protein kinase (MAPK) signaling system, 
nuclear factor kappa B (NFKB) complex, neuropeptide 
Y (NPY) neurotransmission, a nicotine receptor subunit 
(CHRNA2), the vesicular monoamine transporter 
(SLC18A2), genes in pathways linked to human anxiety 
(HTR7, TDO2, and the endozepine-related protein pre-
cursor DKFZP434A2417), and the mu-opioid receptor 
(OPRM1) [150].  
Unfortunately, the results of this genome scan are 
not entirely in agreement with studies using data from 
the Collaborative Study on the Genetics of Alcoholism 
(COGA), which also found some evidence for linkage 
with tobacco use. In COGA, using a dichotomous out-
come of ever/never smoker, a sib-pair analysis found 
support for linkage, particularly to regions on chromo-
somes 6, 9 and 14 [151]. The evidence for linkage was 
weaker when the analysis used a cumulative pack-year 
history as the outcome, although some candidate re-
gions were still noted. Agreement between the findings 
of COGA and the genome scan of Sullivan and col-
leagues occurred in areas found to have only weak or 
equivocal linkage signal in the latter study, on chromo-
somes 4, 6, 9, 14 and 17. However, the COGA analysis 
does correlate to other study findings; two of the three 
markers shared between COGA’s ever/never outcome 
and the pack-years outcome have been previously iden-
tified as associated with smoking; one is the locus for 
DBH, a smoking candidate gene, and the other is for the 
chromosome 5q marker D5S1354. The chromosome 5 
marker was found to be the primary genetic determinant 
of smoking behavior in a separate COGA study pub-
lished that year [152]. Interestingly, this locus is very 
close to the D1 dopamine receptor gene locus, which 
has been previously been associated with smoking 
[153]. Although these findings are intriguing, additional 
linkage and experimental studies need to clarify the 
relevance of these overlaps.   
Linkage studies have potential to support the can-
didacy of the genes discussed in this review. Unfortu-
nately, the analyses published thus far have not appre-
ciably strengthened the evidence for these particular 
genes, such as DRD2 or CYP2A6. Disappointing re-
sults can be partly explained by the fact linkage studies 
have low power when testing genes with modest or 
small effects. A gene with a relative risk of 2 or less 
requires sample sizes that are rarely attainable (>2,500 
families) to obtain 80% power [154]. Inconsistencies 
may also be due to the fact that the currently available 
genetic maps are still imprecise, despite the efforts of 
the Human Genome Initiative toward high-resolution 
physical maps and large-scale sequencing. As the num-
ber of known genes increases with time, directed ge-
nomic screening may at times become more appropriate 
than random genomic screening, which has been the 
primary method of linkage studies of tobacco use [155]. 
In the meantime, direct tests of association, which re-
main powerful despite modest relative risks, are useful 
tools [154]. To direct genomic screening towards the 
best candidates, association studies will need to find 
solutions to their own current limitations, as discussed 
in the following section.  
  
LIMITATIONS AND TRENDS FOR 
FUTURE RESEARCH IN THE GENETICS 
OF TOBACCO USE 
Overall, the role of genetics in determining to-
bacco use seems to be an important yet complex one. 
Much of the difficulty in identifying key genes is the 
fact that they are likely to be numerous, each with small 
effects that together shape various phenotypes associ-
ated with smoking. Despite small effects, genetic poly-
morphisms are of public health significance; their at-
tributable risk is likely to be substantial due to their 
frequency in the population [154]. Unfortunately, stud-
ies of single genes will often suffer from insufficient 
power to find such small effects. Furthermore, there are 
limitations of past studies that make attempts to unify 
their results difficult, and these issues imply certain 
considerations that are necessary in future studies. 
A primary concern here is that the exposure vari-
able used in these studies, namely, one particular gene, 
may be insufficient by itself to detect true associations. 
That is, it is necessary to examine gene-gene interac-
tions and gene-environment interactions. For example, 
while serotonin transporter or DRD4 receptors genes 
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gations considering their interaction with environmental 
factors found that these gene variants are important 
with certain personality types or when subjects are pre-
sented with smoking cues. In future studies, the insuffi-
cient power offered by studying one single locus may 
be partly overcome by studying haplotypes or the asso-
ciation of multiple polymorphisms within and around 
an unknown polymorphism of significance. While fam-
ily studies are needed to construct haplotypes, associa-
tion studies can use statistical methods to estimate 
haplotype frequencies. Either a single haplotype, or a 
subgroup of more than one haplotype, may be of greater 
frequency in cases than in controls, indicating haplo-
type or allelic heterogeneity [58]. Implicated genes may 
then be investigated in animal models to establishing 
possible mechanisms of action.  
A separate reason for reduced power in past stud-
ies may involve the recent finding that heterosis occurs 
with certain genes and smoking behavior [106]. This 
finding suggests that in future studies, comparing the 
frequency of heterozygotes and genotype distribution 
may have better discriminative power than comparing 
gene frequency [156]. Furthermore, false negatives may 
be reduced if gender differences and gender-specific 
heterosis are considered in the analysis of association 
studies [106]. In the D2 gene, for example, studies have 
found that the effects of variants are in opposite direc-
tions for males and females [89,106,107], and heterosis 
has been suggested by one study, where male heterozy-
gotes had significantly higher smoking rates than male 
homozygotes, while female heterozygotes were less 
likely to smoke than female homozygotes [106].  
Inconsistencies across studies are also likely to be 
due to false positives, as the risk of a type I error is 
alarmingly high when the candidate gene approach is 
used. The standard p-value of 0.05 may not be appro-
priate, and its use has led to controversy over how to 
view varying results of studies of complex behaviors 
[157]. The mistake of relying on statistical significance 
to determine the truth of a hypothesis is exacerbated 
when one considers other sources of bias that may also 
lead to false positives. Confounding issues need to be 
anticipated and properly controlled. Although popula-
tion stratification was once thought to be an important 
concern in confounding, it is doubtful that it is the 
cause of much bias in properly designed genetic asso-
ciation studies [158], and if needed, it can be dealt with 
in the design phase by matching on race and ethnicity, 
or in the analysis by testing for its presence, followed 
by adjustment with genomic control (i.e., inflating the 
standard chi-square) or cluster analysis methods [159]. 
Indeed, failure to replicate findings of positive results is 
most likely to be due to issues in poor study design and 
execution, and investigator-reporting bias. Most nota-
bly, ascertainment and selection of cases and control 
subjects, sample size estimation, response rates, and 
laboratory and other measurement error need to be of 
prime concern for researchers [159]. 
 A particular concern in the studies reviewed here 
is the choice of outcome variable. Many analyses use a 
crude dichotomy of smokers vs. non-smokers, paying 
no regard to light or heavy smoking and using various 
definitions of non-smokers. Also, it may be important 
to separate never users of tobacco (i.e., never smoked 
even one cigarette) from non-users (i.e., smoked more 
than one but less than 100 cigarettes) [80,100]. Indeed, 
some genes (e.g. CYP) rely on exposure to tobacco to 
determine the level of their expression or if they will 
even be expressed at all [160], making it is impossible 
to determine the effects of tobacco use when one has 
never been exposed. Another limitation of the exposure 
assessment in these studies is that only cigarette smok-
ing has been taken into account; no information on 
smokeless tobacco, cigar, or pipe use has been incorpo-
rated into tobacco use variables. Misclassification of the 
outcome can obscure meaningful differences between 
groups.  
Meanwhile, studies that have used more specific 
smoking outcomes are difficult to compare due to the 
wide variety of definitions used. Examples of pheno-
types used as outcomes include age of initiation, time to 
nicotine dependence, quantity of use, frequency of use, 
or ability to quit. To facilitate interpretation of findings 
and increase statistical power to detect associations, 
there has recently been a movement towards the use of 
endophenotypes as outcomes in genetic studies. An 
ideal smoking endophenotype would be one that is nar-
rowly defined, readily identifiable, empirically related 
to the clinical manifestation of nicotine dependence, 
and associated with an underlying biological mecha-
nism [161]. Examples include initial sensitivity to nico-
tine, abstinence-induced withdrawal and response to 
different drug challenges [56]. 
In conclusion, to refine the accepted role of ge-
netics in tobacco behavior, there is a need for studies 
that examine multiple genetic polymorphisms and that 
obtain various, detailed smoking-related phenotype 
information. Problems of misclassification, low power, 
and false positives are important not only in and of 
themselves, but also since they may contribute to the 
separate problem of publication bias, in which there is 
94     Maserejian NN, Zavras AI a tendency to publish only positive findings. Still, posi-
tive findings from family studies were able to stimulate 
association studies of genes and smoking behavior. 
Thus far, results in the serotonin transporter gene, do-
pamine transporter gene, dopamine receptor genes D2 
and D4, and cytochrome P450 2A6 have provided the 
most compelling evidence of a connection with smok-
ing behavior. Future association studies, coupled with 
linkage analysis in family studies, will provide deeper 
insight into the relationship between genes, the envi-
ronment and tobacco use. Undoubtedly, knowledge of 
the underlying biological processes involved in the ad-
diction of various smokers will lead to the identification 
of different types of smokers. Patient-specific therapy 
and therefore more effective and efficient treatment for 
tobacco dependence will soon follow. 
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